Tatva Chintan Pharma Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +75% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
TC

Tatva Chintan Pharma Chem Ltd

Q2 FY26Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹124Cr
+49.4% YoY
+6% QoQ
Net profit
₹10Cr
Turned profitable YoY
+42.9% QoQ
Margin
18%
+11 pp YoY
+3 pp QoQ
Price₹1,616
Market cap₹4.0K Cr
P/E76.8

The short version

SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.

From Tatva Chintan Pharma Chem Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters.
  • Agro Products: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027.
  • Electrolyte Salts: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispatches.
  • Pharma and Agro Intermediates: Four agro and four pharma molecules expected to reach full potential in 2-3 years, collectively addressing a revenue potential of INR300-350 crore.

2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
  • This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates.
  • Additional capex rounds may be considered for scaling up certain agro products as demand grows.
  • Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year.

2 more points from Tatva Chintan Pharma Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization.
  • Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback.
  • Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline.
  • New large-scale agro intermediate commercialization has commenced, with production activities progressing as planned.
  • Validation batches for new pharma and agro intermediates are underway, with commercialization expected from December 2025 to the second half of 2026.
  • The semiconductor product pipeline includes products in piloting, with expected revenues ranging INR50-100 crores.

2 more points from Tatva Chintan Pharma Chem Ltd's call on order book

Create a free account to keep reading this call

Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Tatva Chintan Pharma Chem Ltd Q2 FY26 results — key figures

Tatva Chintan Pharma Chem Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue12483+49.4%117+6%
Operating profit (EBITDA)226+266.7%17+29.4%
Operating margin18%7%+11 pp15%+3 pp
Profit before tax14-1—9+55.6%
Net profit (PAT)10-1—7+42.9%
EPS (₹)4.24-0.28—2.84+49.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Gujarat Alkalies (Q2 FY26)

    2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Dynemic Products (Q2 FY26)

    Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a

  • Platinum Industr (Q2 FY26)

    Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri

  • IVP (Q2 FY26)

    Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Tatva Chintan Pharma Chem Ltd Q2 FY26 results?

SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.

What is Tatva Chintan Pharma Chem Ltd share price analysis?

Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.

Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?

A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.

Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.